sinovac COVID-19 vaccine

whole virus inactivated SARS-CoV-2 vaccine produced using Vero cells. Do no confuse with either Sinopharm vaccine

Also Known As:

CoronaVac; CoronaVac antigen; CoronaVac vaccine; Picovacc; Picovacc antigen; SARS-CoV-2 CN2 strain beta-propiolactone inactivated vaccine antigen; inactivated covid-19 cn2 strain vaccine antigen; sinovac COVID vaccine; sinovac COVID vaccine antigen

Networked: 399 relevant articles (50 outcomes, 82 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Inactivated Vaccines: 1604
      - sinovac COVID-19 vaccine: 399
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        sinovac COVID-19 vaccine: 399

Experts

1.	Li, Xue: 14 articles (11/2022 - 01/2022)
2.	Chui, Celine Sze Ling: 11 articles (11/2022 - 01/2022)
3.	Lai, Francisco Tsz Tsun: 11 articles (11/2022 - 01/2022)
4.	Wan, Eric Yuk Fai: 11 articles (11/2022 - 01/2022)
5.	Wong, Ian Chi Kei: 11 articles (11/2022 - 01/2022)
6.	Chan, Esther Wai Yin: 10 articles (11/2022 - 01/2022)
7.	Wong, Carlos King Ho: 10 articles (11/2022 - 01/2022)
8.	Bonfa, Eloisa: 8 articles (10/2022 - 10/2021)
9.	Hung, Ivan Fan Ngai: 6 articles (08/2022 - 01/2022)
10.	Medeiros-Ribeiro, Ana C: 6 articles (07/2022 - 10/2021)

Related Diseases

1.	COVID-19 01/01/2022 - "Our results suggest that a homologous or heterologous booster dose for individuals with a complete primary vaccination schedule with CoronaVac provides a high level of protection against COVID-19, including severe disease and death. " 01/01/2021 - "CoronaVac has high efficacy against PCR-confirmed symptomatic COVID-19 with a good safety and tolerability profile. " 01/01/2021 - "Neutralising antibody titres induced by the 3 μg dose were similar to those of the 6 μg dose, and higher than those of the 1·5 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials to assess protection against COVID-19. " 11/30/2022 - "The overall efficacy for the prevention of symptomatic COVID-19 (before the emergence of variants of concern) using two doses of 3 μg CoronaVac was 67.7% (95% CI, 35.9% to 83.7%). " 12/31/2022 - "The CoronaVac vaccine was found to be effective against symptomatic COVID-19 and protective against severe disease in phase 3 studies. "
2.	Infections 01/01/2023 - "CoronaVac provides some protection against infection of both WH-09 and the Omicron variant in the nude-hACE2 mice. " 11/18/2022 - "Prior infection improved protection in the CoronaVac vaccinees. " 01/01/2022 - "Two doses of CoronaVac in children during the Omicron period showed low levels of protection against symptomatic infection, and modest levels against severe illness." 12/01/2023 - "We showed that 2-dose of CoronaVac effectively induced both ADCP and ADNP, but was substantially lower compared to infection, whereas the booster dose further augmented ADCP and ADNP responses, and remained detectable for 52 weeks. " 08/01/2023 - "Significantly higher levels of anti-spike Abs were observed in the ChAdOx1 group after two doses of vaccination (1975 AU/mL) compared to those who had recovered from natural infection (468.5 AU/mL) and individuals who had received CoronaVac (554.4 AU/mL). "
3.	Neoplasms (Cancer) 01/01/2023 - "Antibody levels measured after two doses of CoronaVac were significantly lower in patients with cancer than in the control group (median 0 μg/ml [IQR 0-1.17 μg/ml] vs median 0.91 μg/ml [IQR 0-2.24 μg/ml], respectively, P = .002). " 09/26/2022 - "There was no statistical difference in the immune response following the third-dose vaccination between cancer patients and healthy individuals who received the same heterologous CoronaVac/ChAdOx1 vaccination. " 01/01/2023 - "The present study revealed that the Sinovac-CoronaVac vaccine showed an acceptable immunogenicity following two shots in cancer patients who were receiving active systemic therapy. " 11/01/2021 - "Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. " 11/01/2021 - "Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy."
4.	Severe Acute Respiratory Syndrome 01/01/2022 - "The aim of this study was to present interim results of our ongoing study to compare the effect of two doses of inactivated CoronaVac vaccine on humoral immunity of people who had previously severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and those people who did not have the infection. " 04/01/2023 - "This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioNTech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in Türkiye. " 01/01/2023 - "A total of 28 coronavirus disease 2019 polymerase chain reaction test-positive sarcoidosis patients who were infected with severe acute respiratory syndrome coronavirus-2 in the past 6 months and did not have coronavirus disease 2019 vaccination and 28 sarcoidosis patients who were administered with 2 doses of CoronaVac and never had coronavirus disease 2019 were included in this study. " 11/04/2022 - "Volunteers were 18-55 years old and randomized at a 1:1 ratio to receive either TURKOVAC or CoronaVac at Day 0 and Day 28, both of which are 3 μg/0.5 mL of inactivated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) adsorbed to aluminum hydroxide. " 01/28/2022 - "Effectiveness of China's 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness against more severe coronavirus disease 2019 (COVID-19). "
5.	Rheumatic Diseases (Rheumatism) 10/01/2021 - "We initiated a prospective phase 4 controlled trial (no. NCT04754698, CoronavRheum) in 910 adults with autoimmune rheumatic diseases (ARD) and 182 age- and sex-frequency-matched healthy adults (control group, CG), who received two doses of CoronaVac. " 01/01/2023 - "Given increased acceptance of the CoronaVac, there is an unmet need to assess the safety and immunogenic changes of CoronaVac in patients with rheumatic diseases (RD). " 01/01/2023 - "Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVac." 10/03/2022 - "Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients." 02/01/2022 - "By contrast with seronegative patients with autoimmune rheumatic diseases, seropositive patients have a robust response after a single dose of CoronaVac. "

Related Drugs and Biologics

1.	BNT162 Vaccine
2.	Vaccines
3.	ChAdOx1 nCoV-19
4.	COVID-19 Vaccines
5.	mRNA Vaccines
6.	N-methyl-valyl-amiclenomycin (BA 2)
7.	2019-nCoV Vaccine mRNA-1273
8.	Inactivated Vaccines
9.	BIBP COVID-19 vaccine
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Electrodes (Electrode)
2.	Therapeutics
3.	Renal Replacement Therapy (Therapies, Renal Replacement)
4.	Intramuscular Injections
5.	Renal Dialysis (Hemodialysis)